Newsbenzinga
Regeneron Pharmaceuticals, Sanofi Amend License, Collaboration Agreement To Jointly Develop, Commercialize Four New Regeneron-Invented Antibodies; Regeneron Anticipates Pre-Tax Acquired In-Process Research And Development Charge Of ~$22M
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…